Superior Anti-Tumor Activity of the MDM2 Antagonist Idasanutlin and the BCL-2 Inhibitor Venetoclax in P53 Wild-Type Acute Myeloid Leukemia Models

Journal of Hematology and Oncology - United Kingdom
doi 10.1186/s13045-016-0280-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase 1 Study of the MDM2 Antagonist RO6839921 in Patients With Acute Myeloid Leukemia

Investigational New Drugs
OncologyPharmacology
2020English

Expression Profile of BCL-2, BCL-XL, and McL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Acute Myeloid Leukemia Drug Development in the Post‐Venetoclax Era

American Journal of Hematology
Hematology
2019English

Clinical Experience With the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies

American Journal of Hematology
Hematology
2017English

Combining Bh3-Mimetics to Target Both BCL-2 and McL1 Has Potent Activity in Pre-Clinical Models of Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2018English

Inhibition of CHK1 Enhances Cell Death Induced by the BCL-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

Oncotarget
Oncology
2016English

MDM2 Inhibitor, Nutlin 3a, Induces P53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation

PLoS ONE
Multidisciplinary
2015English

Hydroxyurea Synergizes With Valproic Acid in Wild-Type P53 Acute Myeloid Leukaemia

Oncotarget
Oncology
2016English

Targeting Autophagy Potentiates the Anti-Tumor Effect of PARP Inhibitor in Pediatric Chronic Myeloid Leukemia

AMB Express
Applied MicrobiologyBiotechnologyBiophysics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy